Last updated: February 19, 2026
Which companies manufacture or supply BESIFLOXACIN HYDROCHLORIDE?
BESIFLOXACIN HYDROCHLORIDE is a fifth-generation fluoroquinolone antibiotic. Its primary suppliers include pharmaceutical companies involved in active pharmaceutical ingredient (API) manufacturing and bulk drug distribution.
Major Suppliers and Manufacturers
| Company |
Location |
Capacity |
Notes |
| Novartis AG |
Switzerland |
Large |
Produces BESIFLOXACIN API for global markets. |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
Moderate |
Significant API producer serving Asia, exporting globally. |
| Zhejiang Coremed Co., Ltd. |
China |
Small |
Supplies in China and Southeast Asia markets. |
| Aurobindo Pharma Ltd. |
India |
Large |
Engages in API manufacturing, including fluoroquinolones. |
| Midas Pharma |
Germany |
Contract Manufacturing |
Provides supply chain services, sourcing from multiple manufacturers. |
Supply Sources and Market Distribution
- Authorized API producers predominantly operate in India and China, with European companies involved mainly in formulation manufacturing.
- Generic drug manufacturers often source BESIFLOXACIN HYDROCHLORIDE from these primary API producers.
- Regulatory Status: API suppliers usually hold certifications from WHO, USFDA, or EMA, indicating compliance with Good Manufacturing Practices (GMP).
Global API Market Dynamics
- The API sector for fluoroquinolones, including BESIFLOXACIN, faces supply chain challenges that include regulatory variations, capacity constraints, and price competition.
- Chinese and Indian API producers dominate global supply, accounting for over 80% of fluoroquinolone API production.[1]
- Major pharmaceutical companies often engage in vertical integration, controlling both API production and finished drug formulation.
Regulatory and Quality Considerations
- Suppliers must meet international standards such as GMP compliance.
- Certification from agencies like USFDA and EMA is crucial for API acceptance by major markets.
- Some suppliers hold ISO certifications specifically relevant for chemical manufacturing.
Who are the primary buyers?
- International generic pharmaceutical companies.
- Regional pharmaceutical firms in Asia, Europe, and North America.
- Contract manufacturing organizations (CMOs) providing formulation and finished dosage forms.
Supply Chain Risks
- Political and regulatory changes in China and India affect API availability.
- Capacity limitations in API producers can cause shortages.
- Quality compliance issues may disrupt supply chains.
Summary
The principal sources of BESIFLOXACIN HYDROCHLORIDE API are Chinese and Indian manufacturers with capacity aligned to global demand. Larger pharmaceutical firms tend to have vertical integration or seek bulk API suppliers with GMP certification. Supply chain stability hinges on geopolitical factors, regulatory compliance, and capacity expansion.
Key Takeaways
- Main API suppliers are Novartis (Switzerland), Jiangsu Hengrui (China), Aurobindo Pharma (India), Zhejiang Coremed (China), and Midas Pharma (Germany).
- API production is concentrated in China and India, representing over 80% of the global fluoroquinolone API market.
- Suppliers must meet GMP standards, and regulatory certifications influence market access.
- Supply chain disruptions are possible due to capacity, geopolitical, and regulatory issues.
FAQs
1. How does API quality impact drug safety?
API quality directly affects drug efficacy and safety. Poor-quality API can lead to contamination, reduced potency, or adverse reactions, hence suppliers holding GMP and international certifications become critical.
2. Are there regional restrictions on BESIFLOXACIN HYDROCHLORIDE API?
Regulatory agencies such as USFDA, EMA, and Chinese NMPA may impose restrictions, affecting API export capabilities. Suppliers with multiple certifications reduce risk.
3. What is the typical lead time for BESIFLOXACIN API orders?
Lead times range from 4 to 12 weeks, depending on supplier capacity, order volume, and regulatory clearance.
4. Is BESIFLOXACIN HYDROCHLORIDE API available from multiple suppliers?
Yes, but larger, certified producers dominate the supply chain. Diversification reduces supply risk.
5. How are supply chain risks mitigated in this sector?
Through multiple supplier agreements, certifications, buffer inventories, and sourcing from diversified regions.
References
[1] McKinsey & Company. (2022). Global Active Pharmaceutical Ingredient Market: Trends and Outlook.
[2] US Food and Drug Administration. (2022). Good Manufacturing Practices (GMP) Guidelines.
